12 research outputs found

    Monitoring of transplanted liver health by quantification of organ-specific genomic marker in circulating DNA from receptor.

    Get PDF
    BACKGROUND: Health assessment of the transplanted organ is very important due to the relationship of long-term survival of organ transplant recipients and health organ maintenance. Nowadays, the measurement of cell-free DNA from grafts in the circulation of transplant recipients has been considered a potential biomarker of organ rejection or transplant associated complications in an attempt to replace or reduce liver biopsy. However, methods developed to date are expensive and extremely time-consuming. Our approach was to measure the SRY gene, as a male organ biomarker, in a setting of sex-mismatched female recipients of male donor organs. METHODS: Cell-free DNA quantization of the SRY gene was performed by real-time quantitative PCR beforehand, at the moment of transplantation during reperfusion (day 0) and during the stay at the intensive care unit. Beta-globin cell-free DNA levels, a general cellular damage marker, were also quantified. RESULTS: Beta-globin mean values of patients, who accepted the graft without any complications during the first week after surgery, diminished from day 0 until patient stabilization. This decrease was not so evident in patients who suffered some kind of post-transplantation complications. All patients showed an increase in SRY levels at day 0, which decreased during hospitalization. Different complications that did not compromise donated organs showed increased beta-globin levels but no SRY gene levels. However, when a donated organ was damaged the patients exhibited high levels of both genes. CONCLUSION: Determination of a SRY gene in a female recipient's serum is a clear and specific biomarker of donated organs and may give us important information about graft health in a short period of time by a non-expensive technique. This approach may permit clinicians to maintain a close follow up of the transplanted patient

    Serum SRY gene and beta-globin gene circulating levels in two re-transplanted female patients.

    No full text
    <p>Concentration of serum SRY gene and beta-globin gene circulating levels in two female patients who underwent two consecutive transplantations, one sex-mismatched donor–recipient and the other sex-matched. A) woman who underwent a liver transplantation from a male donor and re-transplanted from a female donor due to hepatic veins thrombosis complication. B) woman who underwent a liver transplantation from a woman donor and re-transplanted from a male donor due to a hepatic artery thrombosis. PT: pre-transplantation sample before organ reperfusion.</p

    Concentration of serum beta-globin levels in patients without complications.

    No full text
    <p>Mean concentration of serum beta-globin circulating levels from patients who accepted transplanted livers without any complications during the first week of stay at ICU (patient 1 to 6, mean <u>+</u>SEM). (*) Kruskall Wallis test, p<0.05; Dunn's Multiple Comparison Test, p<0.05 vs day 0.</p

    Profile of SRY and beta-globin genes circulating levels of two patients with severe complications after transplantation.

    No full text
    <p>A) Patient 7 was transplanted due to a co-infection of HBV and delta virus and after arterial thrombosis was urgently re-transplanted. B) Patient 8 suffered sustained a biliary complication after transplantation that ended in cholestasis. Patient was discharged on day 23 but she was re-admitted to the ICU and suffered a multi-organic failure (MF) on day 37. Patient died on day 70 after transplantation.</p

    Comparison of serum beta-globin levels in patients with and without complications.

    No full text
    <p>Early mean concentration of serum beta-globin circulating levels from patients who accepted transplanted livers without any complications (white bars; n = 6) and patients suffering any kind of post-transplantation complications during their stay at ICU (shadow bars; n = 4).</p

    Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project

    No full text
    corecore